TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Complementary Food Supplements For Reducing Childhood Undernutrition: The JiVitA-4 Study
Brief Summary: The purpose of this study is to test the impact on child growth of three specially formulated complementary food supplements vs. Plumpy'Doz, a previously tested, commercially available complementary food, and vs. a control group that receives no food. All groups will receive nutrition education related to infant and young child feeding. This will be a cluster-randomised trial in children 6-18 months old in rural Rangpur and Gaibandha in Bangladesh.


Options:
A: Arm Label: Bright Futures; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Maternal focused intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Maternal focused intervention | Arm Label: Ounce of Prevention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Ounce of Prevention | Intervention Type: BEHAVIORAL; Name: Maternal focused intervention; Assigned to Arm(s): Maternal focused intervention | Intervention Type: BEHAVIORAL; Name: Ounce of Prevention; Assigned to Arm(s): Ounce of Prevention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3
C: Arm Label: No food; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Plumpy Doz; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Plumpy Doz | Arm Label: Wheat Soy Blend (WSB++); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Wheat Soy Blend (WSB++) | Arm Label: Chickpea based complementary food supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Chickpea based complementary food supplement | Arm Label: Rice based complementary food supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Rice based complementary food supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Wheat Soy Blend (WSB++); Assigned to Arm(s): Wheat Soy Blend (WSB++) | Intervention Type: DIETARY_SUPPLEMENT; Name: Chickpea based complementary food supplement; Assigned to Arm(s): Chickpea based complementary food supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Rice based complementary food supplement; Assigned to Arm(s): Rice based complementary food supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Plumpy Doz; Assigned to Arm(s): Plumpy Doz
D: Intervention Type: BEHAVIORAL; Name: Promotion of a healthy diet and physical activity; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Avoidance of Alcohol, Drugs, and Tobacco; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism
Brief Summary: Due to the considerable prevalence of anxiety in youth with autism spectrum disorders, this study seeks to establish the efficacy of a modified cognitive behavioral therapy protocol in 50 adolescents versus other available treatment options.


Options:
A: Arm Label: Cognitive-Behavior Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-Behavior Therapy | Arm Label: Treatment as Usual; Type: PLACEBO_COMPARATOR; Interventions: Other: Treatment as Usual | Intervention Type: BEHAVIORAL; Name: Cognitive-Behavior Therapy; Assigned to Arm(s): Cognitive-Behavior Therapy | Intervention Type: OTHER; Name: Treatment as Usual; Assigned to Arm(s): Treatment as Usual
B: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive-behavioral therapy | Arm Label: Waitlist; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Cognitive-behavioral therapy; Assigned to Arm(s): Cognitive Behavioral Therapy
C: Arm Label: Cognitive Behavioral Therapy Condition; Type: EXPERIMENTAL; Interventions: Other: Cognitive Behavioral Therapy | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: OTHER; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy Condition | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): Treatment as Usual
D: Arm Label: Fb-Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Functional Behavior-Based Cognitive Behavioral Therapy | Arm Label: Treatment as Usual (TAU); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Functional Behavior-Based Cognitive Behavioral Therapy; Assigned to Arm(s): Fb-Cognitive Behavioral Therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive Behavioral Therapy for Anxiety Disorders in Adolescents With Autism
Brief Summary: Due to the considerable prevalence of anxiety in youth with autism spectrum disorders, this study seeks to establish the efficacy of a modified cognitive behavioral therapy protocol in 50 adolescents versus other available treatment options.


Options:
A: Arm Label: Cognitive Behavioral Therapy Condition; Type: EXPERIMENTAL; Interventions: Other: Cognitive Behavioral Therapy | Arm Label: Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as usual | Intervention Type: OTHER; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy Condition | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): Treatment as Usual
B: Arm Label: Cognitive Behavioral Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Behavioral Therapy | Arm Label: Treatment as usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment As Usual | Intervention Type: BEHAVIORAL; Name: Cognitive Behavioral Therapy; Assigned to Arm(s): Cognitive Behavioral Therapy | Intervention Type: BEHAVIORAL; Name: Treatment As Usual; Assigned to Arm(s): Treatment as usual
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: family based cognitive behavior therapy | Intervention Type: BEHAVIORAL; Name: family based cognitive behavior therapy; Assigned to Arm(s): 2
D: Arm Label: CBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CBT | Arm Label: WL; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: CBT; Assigned to Arm(s): CBT

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical Evaluation Of NCLE in The Lymph Nodes Along With Masses and Cystic Tumors of the Pancreas
Brief Summary: This study focuses on three different lesions: pancreatic cysts, lymph nodes near the gastrointestinal tract and pancreatic masses.

On one hand, the results obtained during previous studies are more advanced for the assessment of the diagnostic performance of Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system for Pancreatic cysts. Safety and technical feasibility have already been performed, and an interpretation criteria classification exists. On the other hand, results for pancreatic masses and Lymph nodes are less developed.

The study therefore comprises two sub-studies, one on the pancreatic cysts, and another on pancreatic masses and lymph nodes.

1. Cysts The primary hypothesis of the study is that using nCLE in addition to EUS-FNA and tissue sampling allows better characterization of pancreatic cysts and improves appropriate therapeutic decision-making.

   For physicians, integrating nCLE into the diagnostic algorithm of pancreatic cysts could impact patient management by :
   * Ruling out malignancy for patients with benign appearing nCLE images.
   * Characterizing more malignant tumors in the pancreas.
2. Pancreatic masses and Lymph nodes The primary hypothesis of the study is that in vivo imaging of lymph-nodes near the gastrointestinal tract and pancreatic masses during EUS-FNA procedures is feasible and that descriptive criteria can be defined to further differentiate the different types of lesions.


Options:
A: Arm Label: Pancreatic adenocarcinoma; Type: N/A; Interventions: N/A | Arm Label: Chronic pancreatitis; Type: N/A; Interventions: N/A
B: Arm Label: EUS FNA with 2 passes; Type: ACTIVE_COMPARATOR; Interventions: Procedure: EUS FNA with 2 passes | Arm Label: EUS FNA with 4 passes; Type: ACTIVE_COMPARATOR; Interventions: Procedure: EUS FNA with 4 passes | Intervention Type: PROCEDURE; Name: EUS FNA with 2 passes; Assigned to Arm(s): EUS FNA with 2 passes | Intervention Type: PROCEDURE; Name: EUS FNA with 4 passes; Assigned to Arm(s): EUS FNA with 4 passes
C: Arm Label: Lymph nodes, pancreatic masses & cysts; Type: OTHER; Interventions: Procedure: EUS-FNA, Device: nCLE | Intervention Type: PROCEDURE; Name: EUS-FNA; Assigned to Arm(s): Lymph nodes, pancreatic masses & cysts | Intervention Type: DEVICE; Name: nCLE; Assigned to Arm(s): Lymph nodes, pancreatic masses & cysts
D: Arm Label: 1.EUS-FNA with or without suction; Type: EXPERIMENTAL; Interventions: Procedure: 1.EUS-FNA with or without suction | Arm Label: 2.Pushing the stylet or injecting air; Type: EXPERIMENTAL; Interventions: Procedure: 2.Pushing the stylet or injecting air | Intervention Type: PROCEDURE; Name: 1.EUS-FNA with or without suction; Assigned to Arm(s): 1.EUS-FNA with or without suction | Intervention Type: PROCEDURE; Name: 2.Pushing the stylet or injecting air; Assigned to Arm(s): 2.Pushing the stylet or injecting air

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Higher levels of physical activity are associated with better functional status, fewer hospital admissions, and lower mortality. The investigators studied the feasibility and safety of a novel program that combines a pedometer with a website to increase walking. This is a pilot study.


Options:
A: Arm Label: website and pedometer; Type: EXPERIMENTAL; Interventions: Behavioral: website and pedometer | Intervention Type: BEHAVIORAL; Name: website and pedometer; Assigned to Arm(s): website and pedometer
B: Arm Label: MOBILE-A; Type: EXPERIMENTAL; Interventions: Behavioral: Coached exercise persistence intervention | Arm Label: MOBILE-B; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self-Monitored exercise persistence intervention | Intervention Type: BEHAVIORAL; Name: Coached exercise persistence intervention; Assigned to Arm(s): MOBILE-A | Intervention Type: BEHAVIORAL; Name: Self-Monitored exercise persistence intervention; Assigned to Arm(s): MOBILE-B
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Intervention Type: BEHAVIORAL; Name: Supervised aerobic training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Supervised strength training; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Unsupervised training; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Intravenous Lornoxicam is More Effective Than Paracetamol as a Supplemental Analgesic After Lower Abdominal Surgery; A Randomized Controlled Trial
Brief Summary: Background: The aim of this prospective, randomized, double-blind study is to determine the most effective supplemental analgesic, paracetamol or lornoxicam for postoperative pain relief after lower abdominal surgery.

Methods: Sixty patients scheduled for lower abdominal surgery under general anesthesia were randomly allocated to receive either isotonic saline (Control group), intravenous paracetamol 1 g every 6 h (Paracetamol group) or lornoxicam 16 mg then 8 mg after 12 h (Lornoxicam group). Additionally pain was treated postoperatively using morphine patient-controlled analgesia. Postoperative pain scores measured by the verbal pain score (VPS), morphine consumption and the incidence of side effects were measured at 1, 2, 4, 8, 12 and 24 hours postoperatively.


Options:
A: Arm Label: IV Placebo 100 ml; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Placebo | Arm Label: IV Placebo 65 ml; Type: PLACEBO_COMPARATOR; Interventions: Drug: IV Placebo | Arm Label: IV Acetaminophen 1 gm; Type: EXPERIMENTAL; Interventions: Drug: IV Acetaminophen | Arm Label: IV Acetaminophen 650 mg; Type: EXPERIMENTAL; Interventions: Drug: IV Acetaminophen | Intervention Type: DRUG; Name: IV Placebo; Assigned to Arm(s): IV Placebo 100 ml | Intervention Type: DRUG; Name: IV Placebo; Assigned to Arm(s): IV Placebo 65 ml | Intervention Type: DRUG; Name: IV Acetaminophen; Assigned to Arm(s): IV Acetaminophen 1 gm | Intervention Type: DRUG; Name: IV Acetaminophen; Assigned to Arm(s): IV Acetaminophen 650 mg
B: Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Arm Label: Morphine; Type: EXPERIMENTAL; Interventions: Drug: Morphine | Arm Label: Paracetamol-morphine; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol- Morphine | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Morphine; Assigned to Arm(s): Morphine | Intervention Type: DRUG; Name: Paracetamol- Morphine; Assigned to Arm(s): Paracetamol-morphine
C: Arm Label: Lornoxicam; Type: EXPERIMENTAL; Interventions: Drug: Lornoxicam | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Control | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Lornoxicam; Assigned to Arm(s): Lornoxicam
D: Arm Label: Paracetamol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paracetamol | Arm Label: Dipyrone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dipyrone | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Dipyrone; Assigned to Arm(s): Dipyrone

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of Cetuximab in Combination With Chemotherapy for the First Treatment of Metastatic Colorectal Cancer
Brief Summary: In this study, the investigators assessed the effect of Cetuximab in combination with chemotherapy in the treatment of unresectable metastatic colorectal cancer.


Options:
A: Arm Label: Arm A; Type: EXPERIMENTAL; Interventions: Drug: Cetuximab, Drug: chemotherapy of mFOLFOX6 or FOLFIRI | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Drug: chemotherapy of mFOLFOX6 or FOLFIRI | Intervention Type: DRUG; Name: Cetuximab; Assigned to Arm(s): Arm A | Intervention Type: DRUG; Name: chemotherapy of mFOLFOX6 or FOLFIRI; Assigned to Arm(s): Arm A, Arm B
B: Arm Label: bevacizumab and erlotinib (KRAS WT); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab, erlotinib | Arm Label: bevacizumab (KRAS WT); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: bevacizumab (KRAS mutated); Type: ACTIVE_COMPARATOR; Interventions: Drug: bevacizumab | Arm Label: low dose capecitabine (KRAS mutated); Type: ACTIVE_COMPARATOR; Interventions: Drug: low dose capecitabine | Intervention Type: DRUG; Name: bevacizumab, erlotinib; Assigned to Arm(s): bevacizumab and erlotinib (KRAS WT) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab (KRAS WT) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab (KRAS mutated) | Intervention Type: DRUG; Name: low dose capecitabine; Assigned to Arm(s): low dose capecitabine (KRAS mutated)
C: Arm Label: 1Capecitabine + bevacizumab + oxaliplatin + cetuximab; Type: EXPERIMENTAL; Interventions: Drug: 1Capecitabine + oxaliplatin + bevacizumab + cetuximab | Arm Label: 21Capecitabine + bevacizumab + oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: 21Capecitabine + bevacizumab + oxaliplatin | Intervention Type: DRUG; Name: 21Capecitabine + bevacizumab + oxaliplatin; Assigned to Arm(s): 21Capecitabine + bevacizumab + oxaliplatin | Intervention Type: DRUG; Name: 1Capecitabine + oxaliplatin + bevacizumab + cetuximab; Assigned to Arm(s): 1Capecitabine + bevacizumab + oxaliplatin + cetuximab
D: Intervention Type: BIOLOGICAL; Name: cetuximab; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adalimumab on Preventing Postoperative Recurrence of Crohn's Disease
Brief Summary: The present study objective is evaluate Adalimumab efficacy versus Azathioprine efficacy on prevention of endoscopic recurrence (Rutgeerts Index= 2b, 3 or 4) in Crohn´s Disease patients after 52 weeks of treatment.


Options:
A: Arm Label: Infliximab; Type: EXPERIMENTAL; Interventions: Biological: Infliximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: BIOLOGICAL; Name: Infliximab; Assigned to Arm(s): Infliximab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Metronidazole + Azathioprine.; Type: EXPERIMENTAL; Interventions: Drug: Metronidazole, Drug: Azathioprine | Arm Label: Metronidazole + Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metronidazole, Drug: Adalimumab | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole + Azathioprine. | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole + Adalimumab | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Metronidazole + Azathioprine. | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Metronidazole + Adalimumab
C: Intervention Type: DRUG; Name: Probiotic - VSL#3; Assigned to Arm(s): N/A
D: Arm Label: Systematic azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Arm Label: Endoscopy-driven azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine in case of endoscopic recurrence, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Systematic azathioprine group | Intervention Type: DRUG; Name: Azathioprine in case of endoscopic recurrence; Assigned to Arm(s): Endoscopy-driven azathioprine group | Intervention Type: PROCEDURE; Name: Ileocolonoscopy; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group | Intervention Type: PROCEDURE; Name: Small bowel follow trough; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Adalimumab on Preventing Postoperative Recurrence of Crohn's Disease
Brief Summary: The present study objective is evaluate Adalimumab efficacy versus Azathioprine efficacy on prevention of endoscopic recurrence (Rutgeerts Index= 2b, 3 or 4) in Crohn´s Disease patients after 52 weeks of treatment.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: infliximab | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: infliximab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: Azathioprine; Type: EXPERIMENTAL; Interventions: Drug: Azathioprine, Drug: Mesalazine placebo | Arm Label: Mesalazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mesalazine, Drug: Azathioprine placebo | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Azathioprine | Intervention Type: DRUG; Name: Mesalazine; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Azathioprine placebo; Assigned to Arm(s): Mesalazine | Intervention Type: DRUG; Name: Mesalazine placebo; Assigned to Arm(s): Azathioprine
C: Arm Label: Metronidazole + Azathioprine.; Type: EXPERIMENTAL; Interventions: Drug: Metronidazole, Drug: Azathioprine | Arm Label: Metronidazole + Adalimumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metronidazole, Drug: Adalimumab | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole + Azathioprine. | Intervention Type: DRUG; Name: Metronidazole; Assigned to Arm(s): Metronidazole + Adalimumab | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Metronidazole + Azathioprine. | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Metronidazole + Adalimumab
D: Arm Label: Systematic azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Arm Label: Endoscopy-driven azathioprine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Azathioprine in case of endoscopic recurrence, Procedure: Ileocolonoscopy, Procedure: Small bowel follow trough | Intervention Type: DRUG; Name: Azathioprine; Assigned to Arm(s): Systematic azathioprine group | Intervention Type: DRUG; Name: Azathioprine in case of endoscopic recurrence; Assigned to Arm(s): Endoscopy-driven azathioprine group | Intervention Type: PROCEDURE; Name: Ileocolonoscopy; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group | Intervention Type: PROCEDURE; Name: Small bowel follow trough; Assigned to Arm(s): Endoscopy-driven azathioprine group, Systematic azathioprine group

Answer: C